Payment overview · 2025
General Payments
$8,962.51
25 reported records · 4 companies
Healthcare provider profile · identity verified
Padma M Aking, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · PHOENIX, AZ · NPI 1700975893
Verified facts
What the public records show
CMS Open Payments records show Padma M Aking, M.D. received $8,962.51 in general payments during 2025 across 25 reported records.
Janssen Pharmaceuticals, Inc accounted for 99.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Spravato.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 716 claims for Spravato by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 586 records involving 456 distinct recipient NPIs. Public Medicare Part D data also shows 716 claims for Spravato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $8,868.22 | 99.0% | 22 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $42.74 | 0.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $29.20 | 0.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.35 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,250.00 | 3 |
| Food and Beverage | $594.91 | 19 |
| Travel and Lodging | $117.60 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc, Janssen Scientific Affairs, LLC | $8,830.13 | 22 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $80.83 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $29.20 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $29.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SPRAVATO spravato |
2025 | Spravato | 2024 | 716 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
716 | 33 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | SPRAVATO open payments reported associated product |
CMS Open Payments — General Payments 586 supporting records · 456 recipient NPIs · example record 1174147619 |
Spravato · 2024 Exact normalized brand match · 1 Part D row |
716 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Spravato | Esketamine Hcl | 716 | 33 |
| Buspirone Hcl | Buspirone Hcl | 277 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 60 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 237 | 41 |
| Trazodone Hcl | Trazodone Hcl | 234 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 59 |
| Bupropion Xl | Bupropion Hcl | 196 | 45 |
| Sertraline Hcl | Sertraline Hcl | 164 | 44 |
| Lamotrigine | Lamotrigine | 154 | 36 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 128 | 42 |
| Aripiprazole | Aripiprazole | 125 | 21 |
| Alprazolam | Alprazolam | 110 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 31 |
| Mirtazapine | Mirtazapine | 94 | 19 |
| Clonazepam | Clonazepam | 93 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 16 |
| Lurasidone Hcl | Lurasidone Hcl | 75 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 16 |
| Lorazepam | Lorazepam | 56 | 15 |
| Atomoxetine Hcl | Atomoxetine Hcl | 55 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Prazosin Hcl | Prazosin Hcl | 45 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 11 |
| Olanzapine | Olanzapine | 41 | 14 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Gabapentin | Gabapentin | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Lamotrigine Er | Lamotrigine | 15 | suppressed |
| Dexmethylphenidate Hcl Er | Dexmethylphenidate Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Clozaril | Clozapine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,962.51 · 25 records | Janssen Pharmaceuticals, Inc | ARISTADA, FREESTYLE LIBRE 3, INVEGA SUSTENNA, LYBALVI, SPRAVATO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Spravato play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error